Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Buys 10,000 Shares

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. acquired 10,000 shares of the stock in a transaction on Friday, January 17th. The shares were acquired at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the transaction, the director now directly owns 922,334 shares in the company, valued at $2,370,398.38. The trade was a 1.10 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Anixa Biosciences Stock Performance

Shares of ANIX opened at $2.41 on Friday. Anixa Biosciences, Inc. has a 1 year low of $2.07 and a 1 year high of $5.13. The stock has a market capitalization of $77.55 million, a P/E ratio of -6.18 and a beta of 0.90. The company’s fifty day moving average is $2.80 and its two-hundred day moving average is $3.03.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. Sell-side analysts predict that Anixa Biosciences, Inc. will post -0.46 EPS for the current year.

Institutional Trading of Anixa Biosciences

A number of institutional investors have recently modified their holdings of ANIX. International Assets Investment Management LLC lifted its holdings in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after acquiring an additional 23,800 shares during the period. Virtu Financial LLC purchased a new position in shares of Anixa Biosciences in the 3rd quarter valued at about $34,000. Westside Investment Management Inc. lifted its stake in shares of Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares during the period. Concorde Asset Management LLC purchased a new stake in Anixa Biosciences during the second quarter worth about $31,000. Finally, Tyler Stone Wealth Management boosted its holdings in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after buying an additional 21,008 shares in the last quarter. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, January 14th.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.